Inherited factor VII (FVII) deficiency is a rare recessive inherited coagulation disorder with limited available information, especially in patients undergoing major thoracic surgery. In addition, an optimal management strategy for the disease has not been defined. We herein report a case involving a 61-year-old man with asymptomatic FVII deficiency who underwent a right middle and lower lobectomy to treat lung cancer. To the best of our knowledge, the present report is the first to describe the use of recombinant activated FVII continuous infusion for bleeding control after a major thoracic surgery in a patient with inherited FVII deficiency.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11748-014-0455-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk Factors Related to Resting Metabolic Rate-Related Gene Variation in Children with Overweight/Obesity: 3-Year Panel Study.
Nutrients
December 2024
Department of Food & Nutrition & Research Institute of Obesity Sciences, Sungshin Women's University, Dobongro-76gagil-55, Kangbuk-ku, Seoul 01133, Republic of Korea.
Unlabelled: This study investigated how the gene variation related to RMR alteration affects risk factors of obese environments in children with obesity aged 8-9.
Methods: Over a three-year follow-up period, 63.3% of original students participated.
Bleeding Symptoms in Pediatric Patients with Congenital FVII Deficiency and Correlation to Thrombin Generation Assay Parameters: A Single-Center Retrospective Analysis.
Life (Basel)
November 2024
Onco-Hematology, Cell and Gene Therapy and Bone Marrow Transplant Clinic Area, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Inherited factor VII deficiency is the most common rare bleeding disorder, affecting about 1/500,000 individuals without gender predilection. Most of the patients with FVII 20-50% are asymptomatic, but post-traumatic or post-surgical bleeding may often occur since there is not an exact correlation between FVII plasma levels and the bleeding phenotype. We enrolled 19 children and adolescents with FVII levels of 20-35% and 33 controls.
View Article and Find Full Text PDFNew insight into enhanced permanganate oxidation by lignocellulose-derived biochar: The overlooked role of persistent free radicals.
Water Res
December 2024
The Ministry of Education Key Laboratory of Northwest Water Resource, Environment and Ecology, Xi'an University of Architecture and Technology, Xi'an, 710055, PR China; Shaanxi Key Laboratory of Environmental Engineering, Xi'an University of Architecture and Technology, Xi'an, 710055, PR China. Electronic address:
Permanganate (Mn(VII)) is a traditional reagent used for water purification, but it is mild to deal with refractory organic contaminants of emerging concern. There is great interest in combination with effective and low-cost biochar to improve reaction kinetics of Mn(VII). Until recently, it still unclear how biomass composition and carbon structure of biochar influence the Mn(VII) oxidation performance.
View Article and Find Full Text PDFDiagnosis, treatment, surgical practices and review of the literature in rare coagulation factor deficiencies.
Ital J Pediatr
January 2025
Pediatric Hematology and Oncology, SBU Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.
Background: Rare bleeding disorders (RBDs) include fibrinogen (Factor I), prothrombin (Factor II), Factor V(FV), combined Factor V and Factor VIII, Factor VII, Factor X, Factor XI, Factor XII, and Factor XIII deficiencies. This group accounts for 3-5% of all factor deficiencies. Different symptoms may occur, ranging from mild or moderate bleeding to serious and life-threatening bleeding, which may not be related to the factor level.
View Article and Find Full Text PDFAnalysis of the effect of initial hemostasis resuscitation with recombinant human coagulation factor VII a on the treatment of postoperative hemorrhage in cardiac surgery.
J Cardiothorac Surg
January 2025
Cardiac Surgery Critical Care Center Inpatient Ward 1, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Objective: To investigate the effectiveness of initial hemostatic resuscitation(IHR) on the treatment of bleeding with recombinant human coagulation factor VIIa after cardiac surgery.
Methods: The clinical data of patients who received rFVIIa hemostatic treatment after cardiac surgery at Beijing Anzhen Hospital, Capital Medical University, from January 1, 2021, to December 31, 2021 were retrospectively collected. A total of 152 cases were included in the study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!